Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S, dated September 16, 2024, reports the announcement of topline data from the pivotal ApproaCH Trial for TransCon CNP (navepegritide). The trial is a double-blind, placebo-controlled study involving 84 children with achondroplasia (ages 2-11 years) randomized 2:1 to receive once-weekly TransCon CNP or placebo.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and regulatory timelines.
Material Changes and Clinical Results
The ApproaCH Trial demonstrated statistically significant improvements in growth parameters for children treated with TransCon CNP compared to placebo:
- Primary Endpoint (AGV at Week 52): TransCon CNP showed a Least Squares (LS) mean Annualized Growth Velocity (AGV) of 5.89 cm/year versus 4.41 cm/year for placebo, a difference of 1.49 cm/year (p<0.0001).
- Sub-group Analysis (Ages 2 to <5): LS mean AGV was 6.07 cm/year vs. 5.06 cm/year (difference 1.02 cm/year, p=0.0084).
- Sub-group Analysis (Ages 5-11): LS mean AGV was 5.79 cm/year vs. 4.02 cm/year (difference 1.78 cm/year).
- Change from Baseline AGV: Significant improvements observed in both age sub-groups (p=0.0047 for ages 2-<5; p-value not fully specified for ages 5-11 but noted as significant).
- Secondary Endpoints: Significant improvements in ACH Height Z-score (difference 0.28) and CDC Height Z-score (difference 0.30, p=0.0003).
- Safety: The drug was generally well-tolerated with a safety profile comparable to placebo. No serious adverse events were assessed as related to TransCon CNP, and no discontinuations occurred due to adverse events.
Guidance, Outlook, and Risks
Regulatory Timeline: Ascendis plans to submit a New Drug Application (NDA) to the U.S. FDA in Q1 2025 and a Marketing Authorisation Application (MAA) to the European Medicines Agency in Q3 2025.
Forward-Looking Statements: The filing includes standard disclaimers regarding risks such as dependence on third-party manufacturers, unforeseen safety or efficacy results, regulatory delays, and the need for additional funding. Actual results may differ materially from projections.
Investor Verification Checklist
- Verify the specific p-value for the AGV change from baseline in the 5-11 age group, as the text cuts off before stating the value.
- Confirm the exact submission dates for the NDA and MAA as Q1 and Q3 2025 are targets, not guarantees.
- Review the full safety data regarding injection site reactions and long-term monitoring in the open-label extension.
- Assess the company's current cash runway to support commercialization efforts post-approval, as no financial data is provided in this filing.